Bitcoin ETF Approval Triggers $7K Drop; Injective and InQubeta Seen as Leading Picks for 2024 (crypto-news-flash)
The long-standing efforts for a Bitcoin (BTC) spot ETF made it one of the most anticipated developments in the crypto space for a decade. Recently, it became a reality when the SEC’s decision on Bitcoin ETF greenlighted numerous spot Bitcoin ETFs. Due to this victory, BTC faced serious volatility, including a surprising dump of over $7,000.
Some of the more positive performers are Injective (INJ) and InQubeta (QUBE). Since the beginning of this year, INJ has rallied by over 49%, while QUBE recently came through with a solid growth of over 16% to mark the start of its seventh presale stage. Investors are hopeful that the ETF’s impact on crypto prices could prove optimistic for INJ and QUBE, making them top choices to invest in this year.
Let’s explore the effects of ETF approval on Bitcoin while discussing the upside potential of Injective and InQubeta.
InQubeta’s (QUBE) Unique DeFi Offerings Signals Massive Upside Surge
As the crypto industry reacts to the SEC’s decision on Bitcoin ETF, AI-based assets are another sector with rising interest. Future-proof cryptocurrency platforms like InQubeta offer profits from an industry estimated to be worth more than a trillion dollars by the decade’s end. Investors can buy InQubeta NFTs representing investments in AI technologies, and as the AI boom spreads, investors’ holdings will skyrocket, making InQubeta the best crypto investment for long-term profits.
The native QUBE token will power the platform, including its staking pool and other reward programs that make InQubeta the best crypto investment to earn passive income. QUBE is already up 220% from $0.007 to $0.02240. Its current price is 33% less than the $0.0308 price it’s slated to debut on exchanges. Because QUBE will give investors access to the explosive investment offerings of InQubeta, the crypto ICO has been in heavy demand.
InQubeta has successfully sold over 728 million QUBE out of the 975 million allocated to the presale, proving it is selling fast. Just days after its push into the seventh stage of the presale, InQubeta has hit a milestone of over $8.3 million. The platform also has plans to launch cross-chain expansion and multiple innovative partnerships after the crypto ICO, positioning it to become this year’s breakout gem.
Injective’s (INJ) Impressive Rallies Hint At Meteoric Bullish Potential
Since Injective introduced AI into its Layer-1 blockchain ecosystem, cryptocurrency enthusiasts have pegged it as a leading choice for this year’s investment, mainly because AI is one of the hottest trends. Injective was one of the standout performers in the cryptocurrency market last year, and its recent push to a $45 high suggests that it is looking to deliver a more impressive performance this year. The platform has dominated social media conversations because of INJ‘s 3,000% growth in the past year and its surprising 49% surge this month. Analysts are optimistic that INJ could push up to more than $100 when the Bitcoin halving event introduces bullish momentum to the overall market.
Bitcoin’s (BTC) $7,000 Decline Triggered By Bitcoin ETF Approval
After the Bitcoin ETF was launched for investors, BTC skyrocketed to $49,000. This is the first time it’s reached there in almost two years. Shortly after, BTC plummeted to $42,000, recording a more than $7,000 decline. It has since dropped a little further. This performance was projected by multiple analysts, who stated that the ETF’s impact on crypto prices could trigger a sell-the-news campaign and the fall of BTC. Their predictions were backed up by the loss of over $1,500 on Europe’s first Bitcoin ETF when it launched last year. Although the token is currently down, upcoming catalyst events and rising buying pressure on BTC will soon push it higher.
Conclusion
Despite the over $7,000 decline in BTC, the market still has other cryptocurrencies with strong bullish momentum. Injective’s recent surges and InQubeta’s innovative investment approach position them for an impressive 2024. InQubeta’s ongoing presale makes it the token with the higher upside potential, considering the explosive gains that investors stand to rake in after the platform launches. QUBE currently offers a 15% bonus on the presale, making it easy to get in.
from RSS Cryptocurrency News feed https://www.crypto-news-flash.com/bitcoin-etf-approval-triggers-7k-drop-injective-and-inqubeta-seen-as-leading-picks-for-2024/?utm_source=rss&utm_medium=rss&utm_campaign=bitcoin-etf-approval-triggers-7k-drop-injective-and-inqubeta-seen-as-leading-picks-for-2024